ArticleCancer management and research2020
EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling.
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.Molecules (Basel, Switzerland) · 2022Pooled it
- Regulation of epidermal growth factor receptors: The role of c-Cbl, Cdc42, and miRNAs in breast cancer.Biochemistry and biophysics reports · 2026Review
- Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Molecular cancer · 2026Review
- Bioactive Natural Compounds in Triple-Negative Breast Cancer: Molecular Targets and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- LINC00265 is significantly upregulated in breast carcinoma: expression, correlation networks, and potential prognostic value.Molecular biology reports · 2026Article
- An Overview of Emerging Trends in Targeted Therapy of Triple-Negative Breast Cancer.International journal of breast cancer · 2026Review
- Examining the Role of Asef and Epidermal Growth Factor on Cell Migration and Proliferation in Triple Negative Breast Cancer Epithelial Cells.microPublication biology · 2026Article
- Quercetin and Citreorosein fromCurrent pharmaceutical design · 2026Article
- Discovery and molecular characterization of a potent thiazolyl-pyrazole hybrid targeting EGFR for breast cancer therapy.Scientific reports · 2025Article
- ob/ob obese mice promote tumorigenesis of endometrial cancer associated with Pten deficiency.Endocrine-related cancer · 2025Article
- Bibliometric Analysis of The Global Research Trends on The Application of Tamoxifen in The Treatment of Breast Cancer Over The Past 50 Years.The Malaysian journal of medical sciences : MJMS · 2025Review
- Integrating computational methods andHeliyon · 2024Article
- EGFR mutations and abnormal trafficking in cancers.Molecular biology reports · 2024Review
- Prognostic Values of CD8+, PARP, and EGFR on Overall Survival in Patients with Triple-Negative Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Analysis of clinicopathological characteristics and prognostic factors in 54 metaplastic breast carcinoma patients from northwest China.CytoJournal · 2024Article
- Article
- Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors.Cancers · 2023Article
- Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook.Pharmaceutics · 2023Review
- High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients.Cancer medicine · 2023Article
- Proteome of monocled cobra (Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the role of EGFR and STAT3 in breast cancer development and progression.
methodsThrough bioinformatics analysis differently expressed genes (DEGs) including EGFR and STAT3 were identified in breast cancer tissue. QRT-PCR and Western blot analysis were used to investigate EGFR and STAT3 levels in breast cancer tissues and cells. The influence of EGFR and STAT3 on the breast cancer cell proliferation (CCK-8 assay, clone formation assays), migration (wound healing assays) and invasion (transwell assays) were investigated. The influence of EGFR on breast cancer in vivo was examined by Nude mouse transplantation tumor experiments and immunohistochemistry (IHC) staining. The effects of EGFR on breast cancer signaling were assessed via Western blot.
resultsBoth EGFR and p-STAT3 were up-regulated in breast cancer tissues and cell lines. EGFR expression was positively associated with p-STAT3. Moreover, EGFR and p-STAT3 activity enhanced the proliferation and invasion of tumor cells. Breast cancer cell growth was dramatically inhibited by EGFR silencing in vivo.
conclusionEGFR promotes breast cancer progression via STAT3 phosphorylation and JAK/STAT3 signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.